Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $26.4 million.

  • Theravance Biopharma's Operating Expenses fell 454.79% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.1 million, marking a year-over-year increase of 556.07%. This contributed to the annual value of $111.3 million for FY2024, which is 187.64% down from last year.
  • Theravance Biopharma's Operating Expenses amounted to $26.4 million in Q3 2025, which was down 454.79% from $28.9 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Operating Expenses ranged from a high of $98.1 million in Q1 2021 and a low of $21.6 million during Q3 2022
  • Its 5-year average for Operating Expenses is $40.3 million, with a median of $29.9 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 6767.65% in 2022, then soared by 1742.91% in 2024.
  • Quarter analysis of 5 years shows Theravance Biopharma's Operating Expenses stood at $71.1 million in 2021, then plummeted by 54.89% to $32.1 million in 2022, then dropped by 25.8% to $23.8 million in 2023, then grew by 17.43% to $28.0 million in 2024, then decreased by 5.4% to $26.4 million in 2025.
  • Its Operating Expenses stands at $26.4 million for Q3 2025, versus $28.9 million for Q2 2025 and $29.8 million for Q1 2025.